A
A. Karina Eterovic
Researcher at University of Texas MD Anderson Cancer Center
Publications - 6
Citations - 733
A. Karina Eterovic is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: RNA editing & Germline. The author has an hindex of 5, co-authored 6 publications receiving 557 citations.
Papers
More filters
Journal ArticleDOI
The Genomic Landscape and Clinical Relevance of A-to-I RNA Editing in Human Cancers.
Leng Han,Lixia Diao,Shuangxing Yu,Xiaoyan Xu,Xiaoyan Xu,Jie Li,Rui Zhang,Yang Yang,Yang Yang,Henrica M.J. Werner,Henrica M.J. Werner,A. Karina Eterovic,Yuan Yuan,Jun Li,Nikitha Nair,Rosalba Minelli,Yiu Huen Tsang,Lydia W.T. Cheung,Kang Jin Jeong,Jason Roszik,Zhenlin Ju,Scott E. Woodman,Yiling Lu,Kenneth L. Scott,Jin Billy Li,Gordon B. Mills,Han Liang +26 more
TL;DR: The effects of several cross-tumor nonsynonymous RNA editing events on cell viability are experimentally demonstrated and the evidence that RNA editing could selectively affect drug sensitivity is provided, highlighting RNA editing as an exciting theme for investigating cancer mechanisms, biomarkers, and treatments.
Journal ArticleDOI
Characterization of Human Cancer Cell Lines by Reverse-phase Protein Arrays
Jun Li,Wei Zhao,Rehan Akbani,Wenbin Liu,Zhenlin Ju,Shiyun Ling,Christopher P. Vellano,Paul Roebuck,Qinghua Yu,A. Karina Eterovic,Lauren Averett Byers,Michael A. Davies,Wanleng Deng,Y.N. Vashisht Gopal,Guo Chen,Erika von Euw,Dennis J. Slamon,Dylan Conklin,John V. Heymach,Adi F. Gazdar,John D. Minna,Jeffrey N. Myers,Yiling Lu,Gordon B. Mills,Han Liang +24 more
TL;DR: This dataset recapitulates the effects of mutated pathways on protein expression observed in patient samples, and demonstrates that proteins and particularly phosphoproteins provide information for predicting drug sensitivity that is not available from the corresponding mRNAs.
Journal ArticleDOI
Systematic characterization of A-to-I RNA editing hotspots in microRNAs across human cancers.
Yumeng Wang,Yumeng Wang,Xiaoyan Xu,Xiaoyan Xu,Shuangxing Yu,Kang Jin Jeong,Zhicheng Zhou,Leng Han,Yiu Huen Tsang,Jun Li,Hu Chen,Hu Chen,Lingegowda S. Mangala,Yuan Yuan,A. Karina Eterovic,Yiling Lu,Anil K. Sood,Kenneth L. Scott,Gordon B. Mills,Han Liang,Han Liang +20 more
TL;DR: This study systematically characterized the miRNA editing profiles of 8595 samples across 20 cancer types from miRNA sequencing data of The Cancer Genome Atlas and identified 19 adenosine- to-inosine (A-to-I) RNA editing hotspots and independently validated 15 of them by perturbation experiments in several cancer cell lines.
Journal ArticleDOI
Expanded Analysis of Secondary Germline Findings From Matched Tumor/Normal Sequencing Identifies Additional Clinically Significant Mutations
Ecaterina Ileana Dumbrava,Lauren Brusco,Molly S. Daniels,Chetna Wathoo,Kenna R. Shaw,Karen H. Lu,Xiaofeng Zheng,Louise C. Strong,Jennifer K. Litton,Banu Arun,A. Karina Eterovic,Mark J. Routbort,Keyur P. Patel,Yuan Qi,Sarina Anne Piha-Paul,Vivek Subbiah,David S. Hong,Jordi Rodon,Scott Kopetz,John Mendelsohn,Gordon B. Mills,Ken Chen,Funda Meric-Bernstam +22 more
TL;DR: Broader genomic testing is likely to identify additional secondary pathogenic germline alterations, some with potential clinical utility for return to patients and their relatives.
Journal ArticleDOI
Poly ADP-ribose polymerase-1 as a potential therapeutic target in Merkel cell carcinoma.
Renata Ferrarotto,Robert J. Cardnell,Shirley Y. Su,Lixia Diao,A. Karina Eterovic,Victor G. Prieto,William H. Morrisson,Jing Wang,Merrill S. Kies,Bonnie S. Glisson,Lauren Averett Byers,Diana Bell +11 more
TL;DR: This study explores PARP as a therapeutic target in Merkel cell carcinoma by exploring its role as an overexpressed gene in SCLC and response to PARP inhibitors.